Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03330847
Recruitment Status : Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : June 11, 2021
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : September 30, 2021